31 July 2026
Perimenopause pipeline: NK3 drugs, E4, cendifensine
On July 31, 2026, Medscape dated Sarah Amandalore’s report: cendifensine cut moderate-to-severe hot-flash frequency 92% at 12 weeks in phase 2.
The full briefing is in the app.
31 July 2026
On July 31, 2026, Medscape dated Sarah Amandalore’s report: cendifensine cut moderate-to-severe hot-flash frequency 92% at 12 weeks in phase 2.
The full briefing is in the app.